

REFERENCIAS BIBLIOGRÁFICAS

El Centro Oncológico Costarricense ha tomado como referencia para la elaboración de esta herramienta las guías siguientes que se detallan. Un comité médico del centro ha puesto a evaluación los criterios presentados por las guías y tropicalizados al país.

Este tema incluye enlaces a pautas patrocinadas por la sociedad y el gobierno de países y regiones seleccionados de todo el mundo. Actualizaremos estos enlaces periódicamente; Es posible que haya versiones más recientes de algunas pautas disponibles en el sitio web de cada sociedad.

International

[European Association of Urology \(EAU\)-European Society for Radiotherapy and Oncology \(ESTRO\)-International Society of Geriatric Oncology \(SIOG\): Guidelines on prostate cancer – Part I: Screening, diagnosis, and local treatment with curative intent, 2016](#) (published 2017)

[International Society of Urological Pathology \(ISUP\): Testicular cancer consultation conference recommendations for the reporting and staging of testicular germ cell tumors](#) (2017)

[World Health Organization \(WHO\): Classification of testicular germ cell tumours — A review and update](#) (2016)

[International Association for the Study of Lung Cancer \(IASLC\): Atlas of ALK and ROS1 testing in lung cancer, second edition](#) (2016)

[World Health Organization \(WHO\): Position paper on mammography screening](#) (2014)

[International Gastric Cancer Linkage Consortium \(IGLC\): Hereditary diffuse gastric cancer – Updated clinical guidelines with an emphasis on germline CDH1 mutation carriers](#) (2015)

[World Gastroenterology Organisation \(WGO\)/International Digestive Cancer Alliance \(IDCA\): Practice guidelines for colorectal cancer screening](#) (2007)

[International Federation for Cervical Pathology and Colposcopy \(IFCPC\): Clinical guidelines](#)

[World Health Organization \(WHO\): Guidelines on treatment of cervical intraepithelial neoplasia 2–3 and adenocarcinoma in situ – Cryotherapy, large loop excision of the transformation zone, and cold knife conization](#) (2014)

[WHO: Guidelines for screening and treatment of precancerous lesions for cervical cancer prevention](#) (2013)

[WHO: Guidelines on the use of cryotherapy for cervical intraepithelial neoplasia](#) (2011)

Canada

[Canadian Urological Association \(CUA\): Recommendations on prostate cancer screening and early diagnosis](#) (2017)

[Cancer Care Ontario \(CCO\): Position statement on prostate cancer screening using the prostate-specific antigen \(PSA\) test](#) (2017)

[Canadian Task Force on Preventive Health Care \(CTFPHC\): Recommendations on screening for prostate cancer with the prostate-specific antigen test](#) (2014)

[Cancer Care Ontario \(CCO\): Guidelines and advice for complex surgery and perioperative systemic therapy for genitourinary cancer of the retroperitoneum](#) (2019)

[CCO: Guidelines and advice for the management of stage I seminoma](#) (2014)

[CCO: Guidelines and advice on surveillance programs for early stage nonseminomatous testicular cancer](#) (2011)

[CCO: Guidelines and advice on PET imaging in testicular cancer](#) (2009)

[CCO: Guidelines and advice for the management of stage I nonseminomatous testicular cancer](#) (2008)

[Choosing Wisely Canada: Don't perform CT screening for lung cancer among patients at low risk for lung cancer](#) (2017)

[Canadian Association of Radiologists \(CAR\): Guide on CT screening for lung cancer](#) (2016)

[Canadian Task Force on Preventive Health Care \(CTFPHC\): Recommendations on screening for lung cancer](#) (2016)

[CCO: Screening high-risk populations for lung cancer](#) (2013)

[Canadian Task Force on Preventive Health Care \(CTFPHC\): Recommendations on screening for breast cancer in women aged 40–74 years who are not at increased risk for breast cancer, update](#) (2018)

[Cancer Care Ontario \(CCO\): Magnetic resonance imaging screening of women at high risk for breast cancer](#) (2018)

[Choosing Wisely Canada: Don't routinely do screening mammography for average risk women aged 40 – 49. Individual assessment of each woman's preferences and risk should guide the discussion and decision regarding mammography screening in this age group](#) (2018)

[CCO: Breast screening for survivors of breast cancer](#) (2017)

[Choosing Wisely Canada: Don't perform routine cancer screening, or surveillance for a new primary cancer, in the majority of patients with metastatic disease](#) (updated 2017)

[Canadian Association of Radiologists \(CAR\): Practice guidelines and technical standards for breast imaging and intervention](#) (2012, modified 2016)

[Cancer Care Ontario \(CCO\): Staging and surgical approaches in gastric cancer](#) (2017)

[Family Practice Oncology Network \(FPON\): Clinical practice guidelines on upper gastrointestinal cancer \(suspected\)](#) (2016)

[CCO: Systemic therapy for advanced gastric cancer \(2014\)](#)

[Canadian Association of Gastroenterology \(CAG\): Clinical practice guideline on screening for colorectal cancer in individuals with a family history of nonhereditary colorectal cancer or adenoma \(2018\)](#)

[Choosing Wisely Canada: Don't perform routine colonoscopic surveillance every year in patients following their colon cancer surgery; instead, frequency should be based on the findings of the prior colonoscopy and corresponding guidelines \(updated 2017\)](#)

[Canadian Task Force on Preventive Health Care \(CTFPHC\): Recommendations on screening for colorectal cancer in primary care \(2016\)](#)

[Medical Services Commission: British Columbia guidelines for colorectal screening for cancer prevention in asymptomatic patients \(2013, revised 2016\)](#)

[Choosing Wisely Canada: Avoid colorectal cancer screening tests on asymptomatic patients with a life expectancy of less than 10 years and no family history of colorectal neoplasia \(updated 2014\)](#)

[CAG: Position statement on screening individuals at average risk for developing colorectal cancer \(2010\)](#)

[Choosing Wisely Canada: Don't screen women with Pap smears if under 21 years of age or over 69 years of age \(2018\)](#)

[Public Health Agency of Canada \(PHAC\): Canadian Immunization Guide – Human papillomavirus vaccine \(2018\)](#)

[Canadian Task Force on Preventive Health Care \(CTFPHC\): Recommendations on screening for cervical cancer \(2013\)](#)

[Society of Canadian Colposcopists \(SCC\)–Society of Obstetricians and Gynaecologists of Canada \(SOGC\): Joint clinical practice guideline on colposcopic management of abnormal cervical cytology and histology \(2012\)](#)

[SOGC–the Society of Gynecologic Oncology of Canada \(GOC\)–SCC: Joint policy statement on cervical cancer prevention in low-resource settings \(2011\)](#)

United States

[National Cancer Institute \(NCI\): Prostate cancer – Health professional version](#)

[American Urological Association \(AUA\): Early detection of prostate cancer – Guideline \(2013, reviewed 2018\)](#)

[Choosing Wisely: Do not routinely screen for prostate cancer using a prostate-specific antigen \(PSA\) test or digital rectal exam. For men who desire PSA screening, it should only be performed after engaging in shared decision-making \(2013, updated 2018\)](#)

[US Preventive Services Task Force \(USPSTF\): Final recommendation statement on prostate cancer – Screening \(2018\)](#)

[American College of Physicians \(ACP\): Clinical guideline on screening for cancer – Advice for high-value care \(2015\)](#)

[Choosing Wisely: Don't recommend screening for breast, colorectal, or prostate cancer if life expectancy is estimated to be less than 10 years \(2015\)](#)

[Choosing Wisely: Don't recommend screening for breast, colorectal, prostate, or lung cancer without considering life expectancy and the risks of testing, overdiagnosis, and overtreatment \(2014, revised 2015\)](#)

[Choosing Wisely: Don't routinely perform PSA-based screening for prostate cancer \(2015\)](#)

[Choosing Wisely: Offer PSA screening for detecting prostate cancer only after engaging in shared decision making \(2015\)](#)

[ACP: Screening for prostate cancer – A guidance statement \(2013\)](#)

[AUA: PSA testing for the pretreatment staging and posttreatment management of prostate cancer – Best practice statement \(2009, amended 2013\)](#)

[Choosing Wisely: Don't perform PSA testing for prostate cancer screening in men with no symptoms of the disease when they are expected to live less than 10 years \(2013\)](#)

[American Cancer Society \(ACS\): Guideline for the early detection of prostate cancer, update \(2010\)](#)

[American Urological Association \(AUA\): Guideline for the diagnosis and treatment of early stage testicular cancer \(2019\)](#)

[Choosing Wisely: Don't screen for testicular cancer in asymptomatic adolescent and adult males \(2018\)](#)

[American College of Radiology \(ACR\): ACR Appropriateness Criteria® on staging of testicular malignancy \(2016\)](#)

[US Preventive Services Task Force \(USPSTF\): Final recommendation statement on testicular cancer — Screening \(2011\)](#)

[American Society of Clinical Oncology \(ASCO\): Clinical practice guideline on uses of serum tumor markers in adult males with germ cell tumors \(2010\)](#)

[National Cancer Institute \(NCI\): Lung cancer – Health professional version](#)

[American College of Chest Physicians \(CHEST\): Guideline and expert panel report on screening for lung cancer \(2018\)](#)

[American Thoracic Society \(ATS\): Official policy statement for evaluating molecular biomarkers for the early detection of lung cancer – When is a biomarker ready for clinical use? \(2017\)](#)

[ATS: Official society research statement on stakeholder research priorities for smoking cessation interventions within lung cancer screening programs \(2017\)](#)

[American Lung Association \(ALA\): Providing guidance on lung cancer screening to patients and physicians, update \(2015\)](#)

[CHEST/ATS: Policy statement on components necessary for high-quality lung cancer screening \(2015\)](#)

[ATS/CHEST: Official policy statement for implementation of low-dose computed tomography lung cancer screening programs in clinical practice \(2015\)](#)

[Choosing Wisely: Don't recommend screening for breast, colorectal, prostate, or lung cancer without considering life expectancy and the risks of testing, overdiagnosis and overtreatment \(2014, revised 2015\)](#)

[American College of Radiology \(ACR\)-Society of Thoracic Radiology \(STR\): Practice parameter for the performance and reporting of lung cancer screening thoracic computed tomography \(CT\) \(2014\)](#)

[American Academy of Family Physicians \(AAFP\): Clinical preventive service recommendation – Lung cancer \(2013\)](#)

[American Cancer Society \(ACS\): Lung cancer screening guidelines \(2013\)](#)

[Choosing Wisely: Don't perform CT screening for lung cancer among patients at low risk for lung cancer \(2013\)](#)

[US Preventive Services Task Force \(USPSTF\): Final recommendation statement – Lung cancer: Screening \(2013\)](#)

[American Association for Thoracic Surgery \(AATS\): Guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups \(2012\)](#)

[American College of Obstetricians and Gynecologists \(ACOG\): Breast cancer screening and treatment – Resource overview](#)

[American Society of Breast Surgeons \(ASBS\): Position statement on screening mammography \(2019\)](#)

[American College of Radiology \(ACR\): ACR Appropriateness Criteria breast pain \(revised 2018\)](#)

[ACR: ACR Appropriateness Criteria breast cancer screening \(revised 2017\)](#)

[ASBS: Consensus guideline on diagnostic and screening magnetic resonance imaging of the breast \(2017\)](#)

[US Preventive Services Task Force \(USPSTF\): Final recommendation statement – Breast cancer: Screening \(2016\)](#)

[American College of Physicians \(ACP\): Clinical guidelines for screening for cancer – Advice for high-value care \(2015\)](#)

[American Cancer Society \(ACS\): Guideline on breast cancer screening for women at average risk, update \(2015\)](#)

[Centers for Disease Control and Prevention \(CDC\): National Breast and Cervical Cancer Early Detection Program \(NBCCEDP\) \(2013, updated 2015\)](#)

[ACR: Breast Imaging Reporting and Data System \(BI-RADS\) Atlas, 5th edition \(2013\)](#)

[ACS: Guidelines for breast screening with MRI as an adjunct to mammography \(2009\)](#)

[United States Multi-Society Task Force \(USMSTF\) on Colorectal Cancer: Recommendations for follow-up after colonoscopy and polypectomy – A consensus update \(2020\)](#)

[American College of Physicians \(ACP\): Screening for colorectal cancer in asymptomatic average-risk adults – A guidance statement \(2019\)](#)

[American Society of Clinical Oncology \(ASCO\): Resource-stratified guideline on early detection for colorectal cancer \(2019\)](#)

[Choosing Wisely: Don't obtain routine blood work \(eg, CBC, liver function tests\) other than a CEA level during surveillance for colorectal cancer \(2016, updated 2019\)](#)

[American Cancer Society \(ACS\): Guideline on colorectal cancer screening for average-risk adults, update \(2018\)](#)

[American College of Radiology \(ACR\): ACR Appropriateness Criteria colorectal cancer screening \(revised 2018\)](#)

[Choosing Wisely: Do not repeat colorectal cancer screening \(by any method\) for 10 years after a high-quality colonoscopy that does not detect neoplasia \(2012, updated 2018\)](#)

[Cystic Fibrosis Foundation \(CFF\): Cystic fibrosis colorectal cancer screening consensus recommendations \(2018\)](#)

[USMSTF on Colorectal Cancer: Consensus guideline for colorectal cancer screening – Recommendations for physicians and patients \(2017\)](#)

[USMSTF on Colorectal Cancer: Recommendations on fecal immunochemical testing to screen for colorectal neoplasia – A consensus statement \(2017\)](#)

[USMSTF on Colorectal Cancer: Recommendations for colonoscopy surveillance after colorectal cancer resection \(2016\)](#)

[US Preventive Services Task Force \(USPSTF\): Final recommendation statement on colorectal cancer – Screening \(2016\)](#)

[American College of Gastroenterology \(ACG\): Clinical guideline on genetic testing and management of hereditary gastrointestinal cancer syndromes \(2015\)](#)

[ACP: Clinical guidelines for screening for cancer – Advice for high-value care \(2015\)](#)

[Choosing Wisely: Don't recommend screening for breast, colorectal, or prostate cancer if life expectancy is estimated to be less than 10 years \(2015\)](#)

[Choosing Wisely: Don't recommend screening for breast, colorectal, prostate, or lung cancer without considering life expectancy and the risks of testing, overdiagnosis, and overtreatment \(2014, revised 2015\)](#)

[Choosing Wisely: Only order Methylated Septin 9 \(SEPT9\) to screen for colon cancer on patients for whom conventional diagnostics are not possible \(2013\)](#)

[USMSTF on Colorectal Cancer: Guidelines for colonoscopy surveillance after screening and polypectomy – A consensus update \(2012\)](#)

[College of American Pathologists \(CAP\), American Society for Clinical Pathology \(ASCP\), and American Society of Clinical Oncology \(ASCO\): HER2 testing and clinical decision making in gastroesophageal adenocarcinoma \(2016\)](#)

[American College of Gastroenterology \(ACG\): Clinical guideline on genetic testing and management of hereditary gastrointestinal cancer syndromes \(2015\)](#)

[American Society for Gastrointestinal Endoscopy \(ASGE\): The role of endoscopy in the management of premalignant and malignant conditions of the stomach \(2015\)](#)

[Advisory Committee for Immunization Practices \(ACIP\): Human papillomavirus \(HPV\) vaccine recommendations](#)

[American Society for Colposcopy and Cervical Pathology \(ASCCP\): Guidelines](#)

[National Cancer Institute \(NCI\): Cervical cancer – Health professional version](#)

[ACIP: Recommended adult immunization schedule for ages 19 years or older, United States \(2020\)](#)

[ACIP: Recommended child and adolescent immunization schedule for ages 18 years or younger, United States \(2020\)](#)

[American Cancer Society \(ACS\): Guideline on cervical cancer screening for individuals at average risk, update \(2020\)](#)

[American College of Obstetricians and Gynecologists \(ACOG\): Committee opinion on human papillomavirus vaccination \(2020\)](#)

[US Preventive Services Task Force \(USPSTF\): Final recommendation statement on cervical cancer – Screening \(2018\)](#)

[ACOG: Committee opinion on cervical cancer screening in low-resource settings \(2015, reaffirmed 2017\)](#)

[American Society of Clinical Oncology \(ASCO\): Resource-stratified clinical practice guideline for the secondary prevention of cervical cancer \(2017\)](#)

[ASCO: Resource-stratified guideline for the primary prevention of cervical cancer \(2017\)](#)

[Choosing Wisely: Don't order screening tests for low-risk HPV types \(2017\)](#)

[Choosing Wisely: Don't perform cervical cytology \(Pap tests\) or HPV screening in immunocompetent women under age 21 \(2017\)](#)

[ACOG: Practice bulletin on cervical cancer screening and prevention](#) (2016)

[ACS: Guidelines for the early detection of cancer – Cervical cancer](#) (2015)

[American College of Physicians \(ACP\): Best practice advice for cervical cancer screening in average-risk women](#) (2015)

[ACP: Clinical guideline for screening for cancer – Advice for high-value care](#) (2015)

[Choosing Wisely: Don't perform screening for cervical cancer in low-risk women aged 65 years or older and in women who have had a total hysterectomy for benign disease](#) (2015)

[Society of Gynecologic Oncology \(SGO\): Use of primary high-risk human papillomavirus testing for cervical cancer screening – Interim guidance](#) (2015)

[ACOG: Practice bulletin on management of abnormal cervical cancer screening test results and cervical cancer precursors](#) (2013)

[Choosing Wisely: Don't screen women older than 65 years of age for cervical cancer who have had adequate prior screening and are not otherwise at high risk for cervical cancer](#) (2013)

[Choosing Wisely: Don't screen women younger than 30 years of age for cervical cancer with HPV testing, alone or in combination with cytology](#) (2013)

Europe

[European Association of Urology \(EAU\): Prostate cancer – Guidelines](#) (2019)

[European Society for Medical Oncology \(ESMO\): Cancer of the prostate – Clinical practice guidelines for diagnosis, treatment, and follow-up](#) (2015, updated 2019)

[EAU-European Society for Radiotherapy and Oncology \(ESTRO\)-International Society of Geriatric Oncology \(SIOG\): Guidelines on prostate cancer – Part I: Screening, diagnosis, and local treatment with curative intent, 2016](#) (published 2017)

[ESMO: Prostate cancer – Consensus conference guidelines, 2012](#) (published 2013)

[European Association of Urology \(EAU\): Testicular cancer guidelines](#) (2019)

[EAU: Guidelines on testicular cancer, update](#) (2015)

[European Society for Medical Oncology \(ESMO\): Consensus conference guidelines on testicular germ cell cancer — Diagnosis, treatment and follow-up](#) (2018)

[ESMO: Clinical practice guidelines on testicular seminoma and non-seminoma](#) (2013, updated 2017)

[European Society of Radiology \(ESR\)/European Respiratory Society \(ERS\): Statement paper on lung cancer screening \(2020\)](#)

[European Society of Thoracic Surgeons \(ESTS\): Recommendations regarding computed tomography screening for lung cancer in Europe \(2017\)](#)

[Breast cancer screening and diagnosis – A synopsis of the European breast guidelines \(2020\)](#)

[European Society for Medical Oncology \(ESMO\): Clinical practice guidelines on gastric cancer \(2016\)](#)

[ESMO–European Society of Surgical Oncology \(ESSO\)–European Society of Radiotherapy and Oncology \(ESTRO\): Clinical practice guidelines for diagnosis, treatment and follow-up for gastric cancer \(2013\)](#)

[European Society of Gastrointestinal Endoscopy \(ESGE\), European Helicobacter Study Group \(EHSG\), European Society of Pathology \(ESP\), and the Sociedade Portuguesa de Endoscopia Digestiva \(SPED\): Guideline for the management of precancerous conditions and lesions in the stomach \(MAPS\) \(2012\)](#)

[European Centre for Disease Prevention and Control \(ECDC\): Immunisation schedules by target disease – Human papillomavirus infection](#)

[European Society for Medical Oncology \(ESMO\): Cervical cancer – Clinical practice guidelines for diagnosis, treatment and follow up \(2017\)](#)

[European guidelines for quality assurance in cervical cancer screening \(2008\)](#)

United Kingdom

[Choosing Wisely UK: Royal College of Pathologists – Unless a patient is at increased risk of prostate cancer because of race or family history, PSA testing does not necessarily lead to a longer life \(2016\)](#)

[Prostate Cancer UK: Consensus statements on PSA testing in asymptomatic men in the UK – Information for health professionals \(2016\)](#)

[Public Health England \(PHE\): Guidance for the prostate cancer risk management programme \(PCRMP\) – Benefits and risks of PSA testing \(2016\)](#)

[Development of a best-practice clinical guideline for the use of bleomycin in the treatment of germ cell tumours in the UK \(2018\)](#)

[Scottish Intercollegiate Guidelines Network \(SIGN\): Management of adult testicular germ cell tumours – A national clinical guideline \(2011\)](#)

[Evidence-based pragmatic guidelines for the follow-up of testicular cancer — Optimising the detection of relapse \(2008\)](#)

[National Academy of Clinical Biochemistry \(NACB\) Laboratory Medicine: Practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers](#) (2008)

[National Institute for Health and Care Excellence \(NICE\): Interventional procedures guidance on laparoscopic retroperitoneal lymph node dissection for testicular cancer](#) (2006)

[National Institute for Health and Care Excellence \(NICE\): Guideline on oesophago-gastric cancer – Assessment and management in adults](#) (2018)

[NICE: Guideline on suspected cancer – Recognition and referral](#) (2015, updated 2017)

[Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland \(AUGIS\), the British Society of Gastroenterology \(BSG\) and the British Association of Surgical Oncology \(BASO\): Guidelines for the management of oesophageal and gastric cancer](#) (2011)

[NICE: Interventional procedures guidance on laparoscopic gastrectomy for cancer](#) (2008)

[British Society of Gastroenterology \(BSG\)/Association of Coloproctology of Great Britain and Ireland \(ACPGBI\)/Public Health England \(PHE\): Post-polypectomy and post-colorectal cancer resection surveillance guidelines](#) (2020)

[BMJ Rapid Recommendations: Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy, or colonoscopy – A clinical practice guideline](#) (2019)

[National Institute for Health and Care Excellence \(NICE\): Diagnostics guidance on quantitative faecal immunochemical tests to guide referral for colorectal cancer in primary care](#) (2017)

[NICE: Diagnostics guidance on virtual chromoendoscopy to assess colorectal polyps during colonoscopy](#) (2017)

[Scottish Intercollegiate Guidelines Network \(SIGN\): Diagnosis and management of colorectal cancer – A national clinical guideline](#) (2011, revised 2016)

[NICE: Clinical guideline for colorectal cancer prevention – Colonoscopic surveillance in adults with ulcerative colitis, Crohn's disease, or adenomas](#) (2011)

[BSG/ACPGBI: Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups, update](#) (2010)

[Public Health England \(PHE\): The Green Book – Human papillomavirus \(HPV\)](#) (2013, updated 2014)

Australia-New Zealand

[Choosing Wisely Australia: Do not perform PSA testing for prostate cancer screening in men with no symptoms and whose life expectancy is less than 7 years](#)

[Royal Australian College of General Practitioners \(RACGP\): Guidelines for preventive activities in general practice – Prostate cancer, 9th edition](#) (2018)

[Prostate Cancer Foundation of Australia \(PCFA\) and Cancer Council Australia \(CCA\): Clinical practice guidelines for PSA testing and early management of test-detected prostate cancer](#) (2016)

[Australian National Health and Medical Research Council \(NHMRC\): Prostate-specific antigen \(PSA\) testing in asymptomatic men \(2014\)](#)

[Healthy Male \(Andrology Australia\): Clinical summary guide on testicular cancer supplement \(2018\)](#)

[Healthy Male \(Andrology Australia\): Clinical summary guide on testicular cancer \(2018\)](#)

[Australia and New Zealand Urogenital and Prostate Cancer Trials Group \(ANZUP\): Stage I testicular cancer surveillance recommendations \(2016\)](#)

[Australian Technical Advisory Group on Immunisation \(ATAGI\): The Australian Immunisation Handbook – Human papillomavirus \(HPV\)](#)

[Royal Australian and New Zealand College of Obstetricians and Gynaecologists \(RANZCOG\): Statement on cervical cancer screening in Australia and New Zealand \(2020\)](#)

[RANZCOG: Guidelines for HPV vaccine \(2019\)](#)

[National Cervical Screening Program \(NCSP\): Guidelines for the management of screen-detected abnormalities, screening in specific populations and investigation of abnormal vaginal bleeding \(2017\)](#)